Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 17

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Pramipexole for Patients with Resistant Obsessive-Compulsive Disorder (OCD)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Pramipexole Dihydrochloride Monohydrate
  • Sponsor:CCAB Centro Clinico Academico Braga Associacao

Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study on Modafinil for Improving Cognitive Deficits in Multiple Sclerosis Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Modafinil
  • Sponsor:CCAB Centro Clinico Academico Braga Associacao

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Carisbamate
  • Sponsor:Sk Life Science Inc.

Long-Term Safety Study of GLM101 for Patients with PMM2-CDG

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alfa-D-Mannopyranosyl Phosphate Dipotassium
  • Sponsor:Glycomine Inc.

Crohn's disease

Recruiting

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Alimentiv Inc.

Colitis ulcerative+2

Recruiting

Study on the Long-term Safety of Guselkumab for Children with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.